RxDoctor Payments Data

Rachel Taliercio, DO

Internal Medicine · Cleveland, OHNPI 1134398712

Payments from drug & device makers

$113,063in general payments, 2019–2025

Across 39 payments — averaging $2899.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$52K
  • GSK$36K
  • Shionogi Inc$24K
  • Medtronic$600
  • AstraZeneca$113
  • Sanofi-aventis U.S. LLC$95

What the payments were for

  • Consulting fees$41,75894%
  • Speaking & faculty fees$6001%
  • Travel & lodging$1,7464%
  • Food & beverage$2391%
  • Education$950%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck9$52,020
GSK18$35,742
Shionogi Inc8$24,493
Medtronic1$600
AstraZeneca2$113
Sanofi-aventis U.S. LLC1$95

How this compares

$113,063 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$38,954
Medicare patients
254
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate22$328,949
NucalaMepolizumab23$164,660
Prolastin CAlpha-1-Proteinase Inhibitor13$152,432
Spiriva RespimatTiotropium Bromide174$115,419
Trelegy ElliptaFluticasone/Umeclidin/Vilanter111$107,693
Fasenra PenBenralizumab14$72,910
Dupixent SyringeDupilumab20$69,920
Dupixent PenDupilumab18$68,903
DuleraMometasone/Formoterol93$41,110
Stiolto RespimatTiotropium Br/Olodaterol Hcl44$36,061
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$32,710
Advair HfaFluticasone Propion/Salmeterol48$29,184
Breo ElliptaFluticasone/Vilanterol33$25,281
SymbicortBudesonide/Formoterol Fumarate40$16,002
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$14,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$35,742$317,887207 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$113$57,152104 claims
MerckDulera$52,020$41,11093 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →